In 2023, European beta-blocking medicine sales reached significant levels, with Germany leading at 685 million Euros. Year-on-year growth varied, with Germany increasing by 0.66%, Italy by 1.52%, and Greece by 0.77%. Portugal showed the highest growth at 2.92%, contrasting with Belgium and Finland, which saw declines of 6.35% and 4.65% respectively. Over the past five years, these sales have experienced varied annual growth rates across countries.
Future trends to watch include advancements in healthcare technology and potential regulatory changes across Europe. These factors could impact market dynamics and country-specific sales performance in the coming years.
Top countries in Beta Blocking Medicine Sales by Country
| # | 6 Countries | Million Euros | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Germany | 685 | 2023 | +0.13% | +0.66% | View data |
| 2 | 2 Italy | 379.7 | 2023 | +1.23% | +1.52% | View data |
| 3 | 3 Greece | 60.8 | 2023 | +0.66% | +0.77% | View data |
| 4 | 4 Belgium | 56.4 | 2023 | -6.62% | -6.35% | View data |
| 5 | 5 Portugal | 39.5 | 2023 | +1.28% | +2.92% | View data |
| 6 | 6 Finland | 17.1 | 2023 | -3.39% | -4.65% | View data |
